Cigna Group $CI Holdings Trimmed by Thoroughbred Financial Services LLC

Thoroughbred Financial Services LLC lessened its holdings in Cigna Group (NYSE:CI) by 26.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,263 shares of the health services provider’s stock after selling 1,570 shares during the period. Thoroughbred Financial Services LLC’s holdings in Cigna Group were worth $1,409,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its position in shares of Cigna Group by 10.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock worth $3,966,690,000 after purchasing an additional 1,094,327 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Cigna Group by 1.1% in the second quarter. Massachusetts Financial Services Co. MA now owns 11,778,472 shares of the health services provider’s stock worth $3,893,727,000 after acquiring an additional 123,479 shares during the last quarter. Dodge & Cox boosted its position in Cigna Group by 1.3% during the first quarter. Dodge & Cox now owns 8,889,733 shares of the health services provider’s stock valued at $2,924,722,000 after purchasing an additional 117,125 shares during the last quarter. GQG Partners LLC grew its stake in Cigna Group by 21.5% in the first quarter. GQG Partners LLC now owns 4,886,674 shares of the health services provider’s stock valued at $1,607,716,000 after purchasing an additional 865,092 shares in the last quarter. Finally, Valeo Financial Advisors LLC raised its stake in shares of Cigna Group by 86,071.1% during the 2nd quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock worth $1,148,859,000 after purchasing an additional 3,471,249 shares in the last quarter. 86.99% of the stock is currently owned by institutional investors and hedge funds.

Cigna Group Stock Performance

NYSE CI opened at $269.52 on Friday. The company’s fifty day moving average is $289.75 and its two-hundred day moving average is $301.13. Cigna Group has a 52-week low of $239.51 and a 52-week high of $350.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.71 and a quick ratio of 0.71. The firm has a market capitalization of $72.00 billion, a price-to-earnings ratio of 14.71, a P/E/G ratio of 0.88 and a beta of 0.44.

Cigna Group (NYSE:CI) last released its earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share for the quarter, beating the consensus estimate of $7.64 by $0.19. Cigna Group had a net margin of 1.92% and a return on equity of 18.80%. The business had revenue of $69.57 billion during the quarter, compared to analysts’ expectations of $66.40 billion. During the same quarter last year, the company earned $7.51 earnings per share. The firm’s revenue was up 9.5% on a year-over-year basis. Cigna Group has set its FY 2025 guidance at 29.600- EPS. Equities research analysts forecast that Cigna Group will post 29.77 EPS for the current year.

Cigna Group Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Thursday, December 4th will be given a $1.51 dividend. This represents a $6.04 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Thursday, December 4th. Cigna Group’s dividend payout ratio (DPR) is 26.64%.

Wall Street Analyst Weigh In

CI has been the topic of several recent research reports. Leerink Partners cut their price objective on shares of Cigna Group from $300.00 to $270.00 in a research report on Friday, October 31st. Wall Street Zen upgraded shares of Cigna Group from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Cantor Fitzgerald lowered their target price on shares of Cigna Group from $365.00 to $325.00 in a research report on Friday, October 31st. UBS Group set a $294.00 price objective on Cigna Group in a report on Wednesday. Finally, Barclays dropped their price target on shares of Cigna Group from $383.00 to $300.00 and set an “overweight” rating on the stock in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $334.05.

Insider Buying and Selling at Cigna Group

In other Cigna Group news, CEO David Cordani purchased 4,134 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average price of $241.88 per share, with a total value of $999,931.92. Following the completion of the transaction, the chief executive officer directly owned 157,935 shares of the company’s stock, valued at approximately $38,201,317.80. This trade represents a 2.69% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian C. Evanko sold 5,368 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $300.00, for a total value of $1,610,400.00. Following the completion of the sale, the insider owned 51,182 shares in the company, valued at approximately $15,354,600. This represents a 9.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.70% of the company’s stock.

Cigna Group Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.